| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.28 | 4e-07 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.43 | 0.0007 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0009 |